Detalhe da pesquisa
1.
Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial.
World J Urol
; 39(1): 65-72, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32189088
2.
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
J Cancer Res Clin Oncol
; 147(1): 235-242, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32886212
3.
[PREFERE - Study on the rise]. / PREFERE-Studie im Aufwind.
Urologe A
; 55(3): 313-7, 2016 Mar.
Artigo
em Alemão
| MEDLINE | ID: mdl-26908120
4.
Correction to: Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
J Cancer Res Clin Oncol
; 147(1): 243-244, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33346877
5.
Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
J Cancer Res Clin Oncol
; 147(4): 1273-1274, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33625578
6.
[Localised prostate cancer: the PREFERE trial]. / Organbegrenztes Prostatakarzinom - PREFERE-Studie.
Z Evid Fortbild Qual Gesundhwes
; 106(5): 333-5; discussion 335, 2012.
Artigo
em Alemão
| MEDLINE | ID: mdl-22818151